Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Patient and Healthcare Provider Satisfaction With Subcutaneous Versus Intravenous Administration of Daratumumab in Combination With Lenalidomide and Dexamethasone as First‐Line Treatment in Patients With Newly Diagnosed Non‐Transplant Eligible Multiple Myeloma: Final Results of the MYLENE Study. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
10.1016/s2352-3026(20)30070-3
10.1016/s2352-3026(20)30070-3 · External reference
10.3324/haematol.2021.279459
10.3324/haematol.2021.279459 · External reference
10.1007/s00432-020-03365-w
10.1007/s00432-020-03365-w · External reference
10.1038/s41408-020-00366-3
10.1038/s41408-020-00366-3 · External reference
10.1111/1475-6773.11194
10.1111/1475-6773.11194 · External reference
10.1007/s12325-024-02985-9
10.1007/s12325-024-02985-9 · External reference
10.1007/s00277-017-3147-y
10.1007/s00277-017-3147-y · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
10.1002/adma.202406604
10.1002/adma.202406604 · External reference
10.1200/op-25-00052
10.1200/op-25-00052 · External reference
